RxDoctor Payments Data

Carmen Staigmiller

Family · Fairfield, MTNPI 1508172719

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Corcept Therapeutics at 52.8% of the total. 2025 is the largest year on record at $191, more than ten times the $13 reported in 2021.

$275in general payments, 2019–2025

Across 12 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$145
  • Novo Nordisk$40
  • ANI Pharmaceuticals, Inc.$28
  • Lilly USA, LLC$19
  • Amgen$18
  • AstraZeneca$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$275 in reported general payments places this provider in the 65th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$45,825
Medicare patients
170
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$20,301
EliquisApixaban24$18,662
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,349
Losartan Potassium156$2,027
Celecoxib17$1,958
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,958
Pantoprazole Sodium139$1,566
Atorvastatin Calcium116$1,391
Calcitonin-SalmonCalcitonin,salmon,synthetic12$1,237
Levothyroxine Sodium154$1,168
Potassium Chloride59$1,086
Tamsulosin Hcl97$1,023
Metoprolol Succinate72$1,016
Rosuvastatin Calcium115$972
Albuterol Sulfate HfaAlbuterol Sulfate28$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$20,30114 claims
PfizerEliquis$12$18,66224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 481 family providers in Montana.

Other family in Fairfield

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →